广西地区非小细胞肺癌中K-ras基因点突变的研究  

Study on Point Mutations of K-ras Gene in Non-small Cell Lung Cancer in Guangxi

作　　者：钟炜祥[1] 陈铭伍[1] 冼磊[1] 李满红[1] 

机构地区：[1]广西医科大学第一附属医院心胸外科,南宁530021

出　　处：《中国肺癌杂志》2011年第6期507-511,共5页Chinese Journal of Lung Cancer

基　　金：广西科学研究与技术开发计划项目(No.10124001A-44);广西研究生教育创新计划项目(No.2010105981002M181)资助~~

摘　　要：背景与目的近期研究显示存在K-ras基因突变的非小细胞肺癌(non-small cell lung cancer, NSCLC)患者对表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)耐药。本研究检测广西地区NSCLC中K-ras基因密码子12、13及61点突变,旨在探讨K-ras基因突变与广西地区NSCLC的关系。方法采用聚合酶链反应-单链构象多态性(polymerase chain reaction-single-strand conformation polymorphism, PCR-SSCP)分析法与PCR-DNA序列分析法联合检测105例新鲜NSCLC手术切除标本和30例癌旁正常肺组织中K-ras基因密码子12、13及61点突变。结果 105例NSCLC癌组织及30例癌旁正常肺组织中无1例发生K-ras基因点突变,本研究选取的NSCLC病例组的K-ras基因突变率为0(0/105)。结论广西地区NSCLC中K-ras基因野生型的比例高,提示广西地区NSCLC患者更能从EGFR-TKIs治疗中获益。Background and objective Recent studies indicated that non-small cell lung cancer （NSCLC） patients with mutant K-ras were resistant to epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKIs）. The aim of this study is to explore the relationship between the mutation of K-ras gene and NSCLC in Guangxi by detecting the point muta-tions in codon 12, 13 and 61 of K-ras gene in NSCLC. Methods The point mutations in codon 12, 13 and 61 of K-ras gene were detected by single-strand conformation polymorphism （SSCP） analysis of polymerase chain reaction （PCR） products and DNA sequencing analysis in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. Results No point muta-tion in codon 12, 13 and 61 of K-ras gene was found in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. In this study, the mutation frequency of K-ras gene in NSCLC was 0 （0/105）. Conclusion The high proportion of K-ras gene in wild-type indicates that patients with NSCLC in Guangxi could take more benefits from the therapy with EGFR-TKIs.

关 键 词：肺肿瘤 K-RAS基因 点突变 

分 类 号：R734.2[医药卫生—肿瘤]